MovDisordV3, France, Analysis, bibRecord, 000629

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

Identifieur interne : 000629 ( France/Analysis ); précédent : 000628; suivant : 000630

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

Auteurs : Rascol [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Janet Poulik [France] ; Umberto Sabatini [France] ; Jean-Michel Senard [France] ; Michèle Ané [France] ; Jean-Louis Montastruc [France] ; André Rascol [France]

Source :

Movement Disorders [ 0885-3185 ] ; 1994.

RBID : ISTEX:6389CD577D0213D1E320DD29FF1012103179B512

English descriptors

KwdEn :
- Aged, Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Dyskinesia, Drug-Induced (drug therapy), Female, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Motor Skills (drug effects), Motor symptoms, Naltrexone, Naltrexone (adverse effects), Naltrexone (therapeutic use), Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson's disease.
MESH :
- chemical , adverse effects : Bromocriptine, Levodopa, Naltrexone.
- chemical , therapeutic use : Bromocriptine, Levodopa, Naltrexone.
- drug effects : Motor Skills, Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- Aged, Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.

Abstract

One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double‐blind, randomized, cross‐over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L‐dopa‐induced peak‐dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.

Url:

https://api.istex.fr/document/6389CD577D0213D1E320DD29FF1012103179B512/fulltext/pdf

DOI: 10.1002/mds.870090410

Affiliations:

Links to Exploration step

ISTEX:6389CD577D0213D1E320DD29FF1012103179B512

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease</title>
<author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name>
</author>
<author><name sortKey="Fabre, Nelly" sort="Fabre, Nelly" uniqKey="Fabre N" first="Nelly" last="Fabre">Nelly Fabre</name>
</author>
<author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
</author>
<author><name sortKey="Poulik, Janet" sort="Poulik, Janet" uniqKey="Poulik J" first="Janet" last="Poulik">Janet Poulik</name>
</author>
<author><name sortKey="Sabatini, Umberto" sort="Sabatini, Umberto" uniqKey="Sabatini U" first="Umberto" last="Sabatini">Umberto Sabatini</name>
</author>
<author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
</author>
<author><name sortKey="Ane, Michele" sort="Ane, Michele" uniqKey="Ane M" first="Michèle" last="Ané">Michèle Ané</name>
</author>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
<author><name sortKey="Rascol, Andre" sort="Rascol, Andre" uniqKey="Rascol A" first="André" last="Rascol">André Rascol</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:6389CD577D0213D1E320DD29FF1012103179B512</idno>
<date when="1994" year="1994">1994</date>
<idno type="doi">10.1002/mds.870090410</idno>
<idno type="url">https://api.istex.fr/document/6389CD577D0213D1E320DD29FF1012103179B512/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003233</idno>
<idno type="wicri:Area/Istex/Curation">003233</idno>
<idno type="wicri:Area/Istex/Checkpoint">003E67</idno>
<idno type="wicri:doubleKey">0885-3185:1994:Rascol:naltrexone:an:opiate</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:7969211</idno>
<idno type="wicri:Area/PubMed/Corpus">004A81</idno>
<idno type="wicri:Area/PubMed/Curation">004A81</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004A96</idno>
<idno type="wicri:Area/Ncbi/Merge">004822</idno>
<idno type="wicri:Area/Ncbi/Curation">004822</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004822</idno>
<idno type="wicri:doubleKey">0885-3185:1994:Rascol O:naltrexone:an:opiate</idno>
<idno type="wicri:Area/Main/Merge">008D23</idno>
<idno type="wicri:Area/Main/Curation">005B32</idno>
<idno type="wicri:Area/Main/Exploration">005B32</idno>
<idno type="wicri:Area/France/Extraction">000629</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease</title>
<author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Clinical Pharmacology (INSERM U317), University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fabre, Nelly" sort="Fabre, Nelly" uniqKey="Fabre N" first="Nelly" last="Fabre">Nelly Fabre</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Neurology (INSERM U 230), University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Pharmacy, University Hospital, Toulouse, University Hospital, Marseille</wicri:regionArea>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Poulik, Janet" sort="Poulik, Janet" uniqKey="Poulik J" first="Janet" last="Poulik">Janet Poulik</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Neurology (INSERM U 230), University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sabatini, Umberto" sort="Sabatini, Umberto" uniqKey="Sabatini U" first="Umberto" last="Sabatini">Umberto Sabatini</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Neurology (INSERM U 230), University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Clinical Pharmacology (INSERM U317), University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ane, Michele" sort="Ane, Michele" uniqKey="Ane M" first="Michèle" last="Ané">Michèle Ané</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, University Hospital, Marseille</wicri:regionArea>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Clinical Pharmacology (INSERM U317), University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rascol, Andre" sort="Rascol, Andre" uniqKey="Rascol A" first="André" last="Rascol">André Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Neurology (INSERM U 230), University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1994">1994</date>
<biblScope unit="vol">9</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="437">437</biblScope>
<biblScope unit="page" to="440">440</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">6389CD577D0213D1E320DD29FF1012103179B512</idno>
<idno type="DOI">10.1002/mds.870090410</idno>
<idno type="ArticleID">MDS870090410</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Bromocriptine (adverse effects)</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Skills (drug effects)</term>
<term>Motor symptoms</term>
<term>Naltrexone</term>
<term>Naltrexone (adverse effects)</term>
<term>Naltrexone (therapeutic use)</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term>
<term>Levodopa</term>
<term>Naltrexone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term>
<term>Levodopa</term>
<term>Naltrexone</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term>
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double‐blind, randomized, cross‐over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L‐dopa‐induced peak‐dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<settlement><li>Marseille</li>
<li>Toulouse</li>
</settlement>
</list>
<tree><country name="France"><noRegion><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name>
</noRegion>
<name sortKey="Ane, Michele" sort="Ane, Michele" uniqKey="Ane M" first="Michèle" last="Ané">Michèle Ané</name>
<name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
<name sortKey="Fabre, Nelly" sort="Fabre, Nelly" uniqKey="Fabre N" first="Nelly" last="Fabre">Nelly Fabre</name>
<name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<name sortKey="Poulik, Janet" sort="Poulik, Janet" uniqKey="Poulik J" first="Janet" last="Poulik">Janet Poulik</name>
<name sortKey="Rascol, Andre" sort="Rascol, Andre" uniqKey="Rascol A" first="André" last="Rascol">André Rascol</name>
<name sortKey="Sabatini, Umberto" sort="Sabatini, Umberto" uniqKey="Sabatini U" first="Umberto" last="Sabatini">Umberto Sabatini</name>
<name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000629 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000629 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:6389CD577D0213D1E320DD29FF1012103179B512
   |texte=   Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.